NCT04634344View on ClinicalTrials.gov

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

DZD2269

A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

15215

University of Pittsburgh Medical Center, Pittsburgh

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea - Seoul St. Marys Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Dizal Pharmaceuticals

INDUSTRY

NCT04634344 - Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | Biotech Hunter | Biotech Hunter